Skip to content
AnalystLens

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 8, 2024)

Reports
Earnings & Results
Filing Date
Filed July 8, 2024
Period End
July 8, 2024
Security
REGN
In the record · 2016–202610-K1110-Q338-K115

REGN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 115 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Aug ’20Aug ’20
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed July 8, 2024. Cited figures are marked; the original filing is the authoritative source.

Regeneron Pharmaceuticals, Inc. has filed a Current Report on Form 8-K to provide preliminary insights into its second quarter 2024 financial results.

The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $24 milliona. This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter. While these figures are preliminary and subject to closing procedures, they offer investors an early look at a specific cost impacting the quarter's profitability.

02—Key points

Key Highlights

  1. Regeneron anticipates an approximate $24 million pre-tax acquired IPR&D charge for Q2 2024.
  2. This charge is related to up-front payments and equity premiums from collaboration and licensing agreements.
  3. The acquired IPR&D charge is expected to reduce Q2 2024 GAAP and non-GAAP net income per diluted share by roughly $0.18.
  4. The company notes that acquired IPR&D charges are variable and not typically forecasted due to uncertainty in timing and magnitude.
  5. The reported financial results for Q2 2024 are preliminary and subject to closing procedures.
  6. The filing includes forward-looking statements and a disclaimer regarding their reliability and the company's obligation to update them.
  7. A note explains the company's use of non-GAAP financial measures and their limitations.

03—Questions

Frequently Asked Questions

  1. What is an 'acquired in-process research and development (IPR&D) charge' and why is it impacting Regeneron's Q2 2024 results?

    An acquired IPR&D charge typically relates to upfront payments, milestone payments, or equity premiums made in connection with collaboration and licensing agreements for research and development projects that are considered in-process. Regeneron expects a charge of approximately $24 million in Q2 2024 due to such agreements, which will negatively affect its net income per share.

  2. How significantly will this IPR&D charge impact Regeneron's earnings per share for the second quarter?

    Regeneron expects this acquired IPR&D charge to decrease both its GAAP and non-GAAP net income per diluted share by approximately $0.18 for the second quarter of 2024. This represents a specific, but relatively small, impact on earnings for the period.

  3. Are the Q2 2024 financial results reported in this 8-K finalized?

    No, the financial results mentioned in this 8-K filing are preliminary and unaudited. They are subject to Regeneron's standard financial statement closing procedures, and actual results may differ.

  4. Why doesn't Regeneron typically forecast acquired IPR&D charges?

    Regeneron explains that acquired IPR&D charges are difficult to forecast because their occurrence, size, and timing depend on future events related to collaborations and licensing agreements, which involve inherent uncertainties.

04—Continue

← View all 8-K filings